

Review Status Updates

Dawn Kimble-Vance, RPh, PN, CAPM Regulatory Project Manager Division of Project Management, ORO, OGD



What is New or Changed? Background:

GDUFA II Commitment Letter (II.B.10)

The Authorized Representative may periodically request a Review Status Update. In response to the Authorized Representative's request, the RPM will timely provide a Review Status Update.



What is New or Changed? Cont'd

- Specific Status Updates added to GDUFA II Commitment Letter
 - During GDUFA I, RPMs received many requests for status updates.
 - We progressed from "check back in 3 months" to provide detailed updates

• Tracking, logging and reporting system for all communications with Applicant as part of GDUFA II



What Does it Mean?

 The Communications MAPP has been updated based on the GDUFA II Commitment Letter

MAPP 5200.3

POLICY AND PROCEDURES

Office of Generic Drugs and Office of Pharmaceutical Quality

Communications with Industry with respect to Abbreviated New Drug Applications



What is the Impact?

• GDUFA II has an organized process for updates

Who is Responsible to do what for Status Updates?



APPLICANT SIDE:


- Authorized representative's responsibility to request a status update
 - Point of contact identified on Form FDA 356h
 - Keep this updated

FDA/OGD SIDE:

Regulatory Project Managers (RPMs) to provide the response within 2 business days

What Will The RPM's Do?





What Will The RPM's Do? Other RPM Touchpoints

- Applicant Status Update requests
- Anticipate a missed Goal Date
- Informally notify applicant of a MAJOR deficiency
- Acknowledgement Letters

FD/

How Will Status Updates be Evaluated?



- RPMs will log all communications
- Periodic evaluations
 - Ensure status update requests do not impede the RPMs workload or progress of other ANDA actions
 - Ensure Applicant requests are value added



What Can Applicants Do to Assist?

- Please note the RPM touchpoints where you will be contacted regarding your ANDA
- If you need a status update outside of those touchpoints, please contact the RPM
 - We ask you do not excessively reach out to the RPM



Resources

- MAPP 5200.3, Communications with Industry with respect to Abbreviated New Drug Applications
- If the assigned RPM is out of the office, reach out to the covering RPM or their Team Leader

https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/ CDER/UCM449543.pdf

